JP2016053057A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016053057A5 JP2016053057A5 JP2015214045A JP2015214045A JP2016053057A5 JP 2016053057 A5 JP2016053057 A5 JP 2016053057A5 JP 2015214045 A JP2015214045 A JP 2015214045A JP 2015214045 A JP2015214045 A JP 2015214045A JP 2016053057 A5 JP2016053057 A5 JP 2016053057A5
- Authority
- JP
- Japan
- Prior art keywords
- angiotensin
- drug
- product according
- diabetic nephropathy
- drug product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- 229940126534 drug product Drugs 0.000 claims 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims 7
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 6
- 208000033679 diabetic kidney disease Diseases 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 239000005541 ACE inhibitor Substances 0.000 claims 5
- 102000008873 Angiotensin II receptor Human genes 0.000 claims 5
- 108050000824 Angiotensin II receptor Proteins 0.000 claims 5
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 5
- 239000003087 receptor blocking agent Substances 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims 4
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims 4
- MOTJMGVDPWRKOC-QPVYNBJUSA-N atrasentan Chemical compound C1([C@H]2[C@@H]([C@H](CN2CC(=O)N(CCCC)CCCC)C=2C=C3OCOC3=CC=2)C(O)=O)=CC=C(OC)C=C1 MOTJMGVDPWRKOC-QPVYNBJUSA-N 0.000 claims 4
- 229950010993 atrasentan Drugs 0.000 claims 4
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims 2
- 230000009286 beneficial effect Effects 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 2
- 230000000877 morphologic effect Effects 0.000 claims 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims 2
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 claims 1
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 claims 1
- 206010001580 Albuminuria Diseases 0.000 claims 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 claims 1
- 239000002083 C09CA01 - Losartan Substances 0.000 claims 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 claims 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims 1
- 239000002081 C09CA05 - Tasosartan Substances 0.000 claims 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 claims 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims 1
- 108010061435 Enalapril Proteins 0.000 claims 1
- 108010007859 Lisinopril Proteins 0.000 claims 1
- UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 claims 1
- 239000005480 Olmesartan Substances 0.000 claims 1
- CYLWJCABXYDINA-UHFFFAOYSA-N Polythiazide Polymers ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CSCC(F)(F)F)NC2=C1 CYLWJCABXYDINA-UHFFFAOYSA-N 0.000 claims 1
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 claims 1
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 claims 1
- 229960004530 benazepril Drugs 0.000 claims 1
- 229960004064 bumetanide Drugs 0.000 claims 1
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 claims 1
- 229960000932 candesartan Drugs 0.000 claims 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 claims 1
- 229960000830 captopril Drugs 0.000 claims 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims 1
- 229960002155 chlorothiazide Drugs 0.000 claims 1
- 229960001523 chlortalidone Drugs 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 229940109239 creatinine Drugs 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 229960000873 enalapril Drugs 0.000 claims 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims 1
- 208000028208 end stage renal disease Diseases 0.000 claims 1
- 201000000523 end stage renal failure Diseases 0.000 claims 1
- 229960004563 eprosartan Drugs 0.000 claims 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 claims 1
- 229960002490 fosinopril Drugs 0.000 claims 1
- 229960003883 furosemide Drugs 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 230000024924 glomerular filtration Effects 0.000 claims 1
- 206010061989 glomerulosclerosis Diseases 0.000 claims 1
- 229960002003 hydrochlorothiazide Drugs 0.000 claims 1
- 229960004569 indapamide Drugs 0.000 claims 1
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 claims 1
- 229960002198 irbesartan Drugs 0.000 claims 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims 1
- 230000003907 kidney function Effects 0.000 claims 1
- 229960002394 lisinopril Drugs 0.000 claims 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims 1
- 229960004773 losartan Drugs 0.000 claims 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 229960002817 metolazone Drugs 0.000 claims 1
- AQCHWTWZEMGIFD-UHFFFAOYSA-N metolazone Chemical compound CC1NC2=CC(Cl)=C(S(N)(=O)=O)C=C2C(=O)N1C1=CC=CC=C1C AQCHWTWZEMGIFD-UHFFFAOYSA-N 0.000 claims 1
- 229960005170 moexipril Drugs 0.000 claims 1
- 229960005117 olmesartan Drugs 0.000 claims 1
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 claims 1
- 229960002582 perindopril Drugs 0.000 claims 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 claims 1
- 229960005483 polythiazide Drugs 0.000 claims 1
- 229920000046 polythiazide Polymers 0.000 claims 1
- 229960001455 quinapril Drugs 0.000 claims 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 claims 1
- 229960003401 ramipril Drugs 0.000 claims 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims 1
- 229960000651 tasosartan Drugs 0.000 claims 1
- ADXGNEYLLLSOAR-UHFFFAOYSA-N tasosartan Chemical compound C12=NC(C)=NC(C)=C2CCC(=O)N1CC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 ADXGNEYLLLSOAR-UHFFFAOYSA-N 0.000 claims 1
- 229960005187 telmisartan Drugs 0.000 claims 1
- 229960005461 torasemide Drugs 0.000 claims 1
- 229960002051 trandolapril Drugs 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 229960004699 valsartan Drugs 0.000 claims 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95730007P | 2007-08-22 | 2007-08-22 | |
| US60/957,300 | 2007-08-22 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013183975A Division JP2014001234A (ja) | 2007-08-22 | 2013-09-05 | 糖尿病の合併症のための療法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017035751A Division JP2017145251A (ja) | 2007-08-22 | 2017-02-28 | 糖尿病の合併症のための療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016053057A JP2016053057A (ja) | 2016-04-14 |
| JP2016053057A5 true JP2016053057A5 (https=) | 2016-07-14 |
Family
ID=40220116
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010522066A Pending JP2010536880A (ja) | 2007-08-22 | 2008-08-22 | 糖尿病の合併症のための療法 |
| JP2013183975A Pending JP2014001234A (ja) | 2007-08-22 | 2013-09-05 | 糖尿病の合併症のための療法 |
| JP2014198604A Pending JP2015028062A (ja) | 2007-08-22 | 2014-09-29 | 糖尿病の合併症のための療法 |
| JP2015214045A Pending JP2016053057A (ja) | 2007-08-22 | 2015-10-30 | 糖尿病の合併症のための療法 |
| JP2017035751A Pending JP2017145251A (ja) | 2007-08-22 | 2017-02-28 | 糖尿病の合併症のための療法 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010522066A Pending JP2010536880A (ja) | 2007-08-22 | 2008-08-22 | 糖尿病の合併症のための療法 |
| JP2013183975A Pending JP2014001234A (ja) | 2007-08-22 | 2013-09-05 | 糖尿病の合併症のための療法 |
| JP2014198604A Pending JP2015028062A (ja) | 2007-08-22 | 2014-09-29 | 糖尿病の合併症のための療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017035751A Pending JP2017145251A (ja) | 2007-08-22 | 2017-02-28 | 糖尿病の合併症のための療法 |
Country Status (5)
| Country | Link |
|---|---|
| US (5) | US20090054473A1 (https=) |
| EP (2) | EP2545920A1 (https=) |
| JP (5) | JP2010536880A (https=) |
| CA (2) | CA2904447C (https=) |
| WO (1) | WO2009026517A2 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070196510A1 (en) * | 2006-02-17 | 2007-08-23 | Gerber Michael J | Method for treating resistant hypertension |
| AU2008282773B8 (en) * | 2007-07-31 | 2013-03-07 | Gilead Sciences, Inc. | Metabolites and derivatives of ambrisentan |
| EP2545920A1 (en) * | 2007-08-22 | 2013-01-16 | Abbott GmbH & Co. KG | Therapy for complications of diabetes |
| CN101632672B (zh) * | 2008-07-24 | 2011-01-12 | 鲁南制药集团股份有限公司 | 一种用于治疗高血压的复方药物组合物 |
| CA2759795C (en) * | 2009-04-30 | 2016-11-29 | Midwestern University | Method and composition for treating diabetic ketoacidosis |
| US9255931B2 (en) | 2010-06-24 | 2016-02-09 | Morehouse School Of Medicine | Method and compositions for the treatment and detection of endothelin-1 related kidney diseases |
| EP2727587A1 (en) * | 2012-10-30 | 2014-05-07 | Pharnext | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level |
| KR20160003128A (ko) | 2013-04-30 | 2016-01-08 | 애브비 인코포레이티드 | 아트라센탄을 사용하는 지질 프로파일을 개선시키기 위한 방법 |
| TWI685348B (zh) * | 2014-05-08 | 2020-02-21 | 美國禮來大藥廠 | 速效胰島素組合物 |
| JP2017534634A (ja) * | 2014-11-07 | 2017-11-24 | アッヴィ・インコーポレイテッド | 体液貯留の予測因子を使用してｃｋｄを処置する方法 |
| JO3749B1 (ar) * | 2015-08-27 | 2021-01-31 | Lilly Co Eli | تركيبات إنسولين سريعة المفعول |
| US10369156B2 (en) * | 2016-11-15 | 2019-08-06 | The George Institute for Global Health | Compositions for the treatment of hypertension |
| KR20240096848A (ko) | 2017-01-25 | 2024-06-26 | 더 조지 인스티튜트 포 글로벌 헬스 | 고혈압의 치료를 위한 조성물 |
| US12521380B2 (en) | 2017-01-25 | 2026-01-13 | The George Institute for Global Health | Compositions for the treatment of hypertension |
| KR102568472B1 (ko) | 2017-02-27 | 2023-08-18 | 이도르시아 파마슈티컬스 리미티드 | 엔도텔린 관련 질환의 치료를 위한 4-피리미딘술파미드 유도체와 활성 성분의 조합물 |
| US20190260657A1 (en) * | 2018-02-21 | 2019-08-22 | Cisco Technology, Inc. | In-band performance loss measurement in ipv6/srv6 software defined networks |
| PL3813942T3 (pl) * | 2018-05-03 | 2024-07-22 | Midwestern University | Kompozycja zawierająca centachinę lub jej sól do zastosowania w leczeniu osobnika cierpiącego na ostre pogorszenie czynności nerek |
| US20210186930A1 (en) * | 2018-05-23 | 2021-06-24 | University Of Miami | Methods of Treating Renal Disease Associated With Chronic Kidney Disease Such as Alport Syndrome |
| MX2021001043A (es) * | 2018-07-26 | 2021-04-12 | The George Inst For Global Health | Composiciones para el tratamiento de hipertension. |
| WO2021087399A1 (en) * | 2019-10-30 | 2021-05-06 | Perfuse Therapeutics, Inc. | Treatment of ocular diseases using endothelin receptor antagonists |
| KR20230015874A (ko) | 2019-12-17 | 2023-01-31 | 치누크 세라퓨틱스, 인크. | 아트라센탄에 의해 iga 신장병증을 치료하는 방법 |
| CN115803028A (zh) | 2020-07-10 | 2023-03-14 | 阿斯利康(瑞典)有限公司 | 用于治疗慢性肾病的齐泊腾坦和达格列净的组合 |
| CA3218251A1 (en) | 2021-04-30 | 2022-11-03 | Perfuse Therapeutics, Inc. | Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases |
| CN116804048B (zh) * | 2023-02-24 | 2024-11-15 | 中国农业大学 | 豌豆白蛋白分离肽、组合物及其用途 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI943071L (fi) * | 1993-06-24 | 1994-12-25 | Takeda Chemical Industries Ltd | Anti-endoteliiniainetta pysyvästi vapauttava valmiste |
| ES2105525T3 (es) * | 1993-06-24 | 1997-10-16 | Lilly Co Eli | 2-fenil-3-aroilbenzotiofenos antiestrogenicos como agentes hipoglicemicos. |
| US6946481B1 (en) * | 1994-08-19 | 2005-09-20 | Abbott Laboratories | Endothelin antagonists |
| US6162927A (en) * | 1994-08-19 | 2000-12-19 | Abbott Laboratories | Endothelin antagonists |
| CA2195677C (en) | 1994-08-19 | 2005-11-08 | Martin Winn | Endothelin antagonists |
| US7208517B1 (en) * | 1994-08-19 | 2007-04-24 | Abbott Labortories | Endothelin antagonists |
| US5767144A (en) * | 1994-08-19 | 1998-06-16 | Abbott Laboratories | Endothelin antagonists |
| US7365093B2 (en) * | 1994-08-19 | 2008-04-29 | Abbott Laboratories | Endothelin antagonists |
| ES2259803T3 (es) | 1996-02-13 | 2006-10-16 | Abbott Laboratories | Nuevos derivados de pirrolidina sustituidos con benzo-1,3-dioxolilo y benzofuranilo como antagonistas de endostelina. |
| US6420412B2 (en) * | 1996-03-29 | 2002-07-16 | Smithkline Beecham Corporation | Eprosartan dihydate and a process for its production and formulation |
| US6121416A (en) * | 1997-04-04 | 2000-09-19 | Genentech, Inc. | Insulin-like growth factor agonist molecules |
| NZ502395A (en) | 1997-08-04 | 2002-08-28 | Abbott Lab | 4-Benzodioxolyl substituted pyrrolidine-3-carboxylic acid derivatives useful as endothelin antagonists |
| US7445792B2 (en) * | 2003-03-10 | 2008-11-04 | Abbott Laboratories | Medical device having a hydration inhibitor |
| US8257725B2 (en) * | 1997-09-26 | 2012-09-04 | Abbott Laboratories | Delivery of highly lipophilic agents via medical devices |
| CA2304712C (en) | 1997-09-26 | 2008-04-29 | Knoll Aktiengesellschaft | Endothelin antagonist and a renin-angiotensin system inhibitor as a combined preparation |
| DE19743142A1 (de) | 1997-09-30 | 1999-04-01 | Knoll Ag | Pharmazeutische Kombinationspräparate |
| DE19743140A1 (de) | 1997-09-30 | 1999-04-01 | Knoll Ag | Pharmazeutische Kombinationspräparate |
| DE19743143A1 (de) | 1997-09-30 | 1999-04-01 | Knoll Ag | Pharmazeutische Kombinationspräparate |
| DE19744799A1 (de) | 1997-10-10 | 1999-04-15 | Knoll Ag | Pharmazeutische Kombinationspräparate |
| DE19754082A1 (de) | 1997-12-05 | 1999-06-10 | Knoll Ag | Methode zur Bekämpfung der Fettleibigkeit |
| EP1114022A1 (en) | 1998-09-14 | 2001-07-11 | Abbott Laboratories | Process for producing stereoselective nitro compounds |
| US8257724B2 (en) * | 1998-09-24 | 2012-09-04 | Abbott Laboratories | Delivery of highly lipophilic agents via medical devices |
| US6238708B1 (en) * | 1999-02-23 | 2001-05-29 | The Iams Company | Composition and process for controlling glucose metabolism in companion animals by dietary starch |
| US6559188B1 (en) * | 1999-09-17 | 2003-05-06 | Novartis Ag | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
| TWI306760B (en) | 2000-08-07 | 2009-03-01 | Abbott Lab | Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same |
| US20020055457A1 (en) * | 2000-08-07 | 2002-05-09 | Janus Todd J. | Methods of treating cancer and the pain associated therewith using endothelin antagonists |
| WO2002017912A1 (en) | 2000-08-31 | 2002-03-07 | Abbott Laboratories | Endothelin antagonists |
| PE20021032A1 (es) | 2001-04-11 | 2002-11-12 | Abbott Lab | Composicion farmaceutica para uso en la modulacion favorable de la calidad de vida relacionada con la salud y progresion temporal ajustada a la calidad relacionada con la salud de una enfermedad en pacientes con cancer de prostata |
| US20030092757A1 (en) * | 2001-04-11 | 2003-05-15 | Amitabh Singh | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer |
| US20030022811A1 (en) * | 2001-04-11 | 2003-01-30 | Amitabh Singh | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer |
| CA2456281A1 (en) * | 2001-09-21 | 2003-04-03 | Novartis Ag | Pyrane derivatives as both ace- and nep- inhibitors |
| WO2003080038A1 (en) * | 2002-03-22 | 2003-10-02 | Kissei Pharmaceutical Co., Ltd. | Preventive or therapeutic agent for kidney disease |
| GB0212412D0 (en) * | 2002-05-29 | 2002-07-10 | Novartis Ag | Combination of organic compounds |
| CL2004000545A1 (es) * | 2003-03-18 | 2005-01-28 | Pharmacia Corp Sa Organizada B | Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul |
| WO2005077413A1 (en) * | 2004-02-11 | 2005-08-25 | Fibrogen, Inc. | Ctgf as target for the therapy of diabetic nephropathy |
| NZ549535A (en) * | 2004-03-17 | 2010-11-26 | Novartis Ag | Use of aliskiren for treating renal and other disorders |
| AU2005222719B2 (en) * | 2004-03-19 | 2011-03-24 | Abbott Laboratories | Multiple drug delivery from a balloon and a prosthesis |
| CA2578824A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form 2 of atrasentan hydrochloride |
| WO2006034234A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form 3 of atrasentan hydrochloride |
| WO2006034085A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form of atrasentan hydrochloride |
| WO2006034094A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form 1 of atrasentan hxdrochloride |
| EP1884513A4 (en) * | 2005-05-23 | 2010-04-28 | Japan Tobacco Inc | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME |
| US20080132710A1 (en) * | 2006-12-04 | 2008-06-05 | Abbott Laboratories | Atrasentan hydrochloride crystalline form 2 |
| EP2545920A1 (en) * | 2007-08-22 | 2013-01-16 | Abbott GmbH & Co. KG | Therapy for complications of diabetes |
| US20100184026A1 (en) * | 2009-01-22 | 2010-07-22 | Abbott Laboratories | Companion Diagnostic Assays For Endothelin Receptor Antagonists |
-
2008
- 2008-08-22 EP EP12182366A patent/EP2545920A1/en not_active Withdrawn
- 2008-08-22 WO PCT/US2008/074013 patent/WO2009026517A2/en not_active Ceased
- 2008-08-22 EP EP08798489A patent/EP2190433A2/en not_active Withdrawn
- 2008-08-22 US US12/196,635 patent/US20090054473A1/en not_active Abandoned
- 2008-08-22 CA CA2904447A patent/CA2904447C/en not_active Expired - Fee Related
- 2008-08-22 JP JP2010522066A patent/JP2010536880A/ja active Pending
- 2008-08-22 CA CA2697057A patent/CA2697057A1/en not_active Abandoned
-
2013
- 2013-02-13 US US13/766,266 patent/US8623819B2/en active Active
- 2013-09-05 JP JP2013183975A patent/JP2014001234A/ja active Pending
- 2013-11-13 US US14/079,464 patent/US8865650B2/en active Active
-
2014
- 2014-09-19 US US14/491,479 patent/US9592231B2/en not_active Expired - Fee Related
- 2014-09-29 JP JP2014198604A patent/JP2015028062A/ja active Pending
-
2015
- 2015-10-30 JP JP2015214045A patent/JP2016053057A/ja active Pending
-
2016
- 2016-12-02 US US15/368,016 patent/US20170079978A1/en not_active Abandoned
-
2017
- 2017-02-28 JP JP2017035751A patent/JP2017145251A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016053057A5 (https=) | ||
| Ruggenenti et al. | Mechanisms and treatment of CKD | |
| Pelletier et al. | Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: Evidence from real-life setting trials and surveys | |
| JP2018507244A5 (https=) | ||
| JP2015536301A5 (https=) | ||
| JP2014513089A5 (https=) | ||
| AR063155A1 (es) | Antagonista del receptor de angiotensina ii para la prevencion o el tratamiento de enfermedades generalizadas en gatos | |
| KR20180018695A (ko) | 항암제 | |
| RU2015110979A (ru) | Комбинации ингибиторов sglt 2 и антигипертензивных лекарственных средств | |
| Chen et al. | Anti tumor activity of selinexor (KPT-330), a first-in-class oral selective inhibitor of nuclear export (SINE) XPO1/CRM1 antagonist in patients (pts) with relapsed/refractory multiple myeloma (MM) or Waldenstrom's macroglobulinemia (WM) | |
| Farsang | Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk | |
| JP2016520135A5 (https=) | ||
| Tanios et al. | Emerging therapies for diabetic nephropathy patients: beyond blockade of the renin-angiotensin system | |
| AR096350A1 (es) | Composición farmacéutica para administración por vía oral para su uso para la prevención y/o el tratamiento de una enfermedad cardiovascular | |
| IT1401284B1 (it) | Nuove formulazioni farmaceutiche idonee per la somministrazione orale di esomeprazolo magnesio diidrato, in forma di compresse mups (multi unit pellets system). | |
| de Zeeuw | Targeting proteinuria as a valid surrogate for individualized kidney protective therapy | |
| Abdel-Rahman et al. | Management of diabetic nephropathy in the elderly: special considerations | |
| AR068814A1 (es) | Composicion farmaceutica que comprende levosimendan y un inhibidor de la enzima conversina de la angiotensina (ace), y uso | |
| Reboldi et al. | Optimal therapy in hypertensive subjects with diabetes mellitus | |
| Lisauskienė et al. | Trends and pattern of the utilization of cardiovascular medicines in Lithuania in 2003–2012 | |
| Vítovec et al. | Fixní kombinace telmisartanu a thiazidového diuretika v léčbě hypertenze | |
| Koh et al. | Calming down chaos regarding redefining blood pressure targets-the importance of statin-based therapy | |
| 정배박 | Antihypertensive drug therapy: a review based on recent guidelines | |
| Jayaram et al. | DIABETIC NEPHROPATHY: MEANS OF PHARMACOLOGICAL INTERVENTION | |
| MX381036B (es) | Sistema multiparticulado de liberación bifásica con predicción de biodisponibilidad modificada de acemetacina. |